Vyome Holdings, Inc
VT - 1953
symptoms of malignant fungating wounds
Countdown
724days
Phase 3 readout · ~ Jun 30, 2028 estimated
What's at stake
Phase 3 trial results for VT - 1953 in symptoms of malignant fungating wounds are due ~ Jun 30, 2028. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“will grow to $1.086B H1 2028 following completion of the Phase 3 study”